A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy ; volume:16 ; number:1 ; day:2 ; month:8 ; year:2016 ; pages:1-11 ; date:12.2016
BMC cancer ; 16, Heft 1 (2.8.2016), 1-11, 12.2016
- Urheber
-
Kim, Sung Han
- Beteiligte Personen und Organisationen
-
Kim, Sohee
Joo, Jungnam
Seo, Ho Kyung
Joung, Jae Young
Lee, Kang Hyun
Chung, Jinsoo
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2615-4
- URN
-
urn:nbn:de:1111-2016080314361
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kim, Sung Han
- Kim, Sohee
- Joo, Jungnam
- Seo, Ho Kyung
- Joung, Jae Young
- Lee, Kang Hyun
- Chung, Jinsoo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
Progression-free or overall survival…revisited in BOLERO-2
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
Venetoclax ex vivo functional profiling predicts improved progression-free survival
Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
A novel DNA methylation signature to improve survival prediction of progression-free survival for testicular germ cell tumors
Intraoperative hypotension is associated with shortened overall survival after lung cancer surgery
Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
Progression-free or overall survival…revisited in BOLERO-2
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
Venetoclax ex vivo functional profiling predicts improved progression-free survival
Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
A novel DNA methylation signature to improve survival prediction of progression-free survival for testicular germ cell tumors
Intraoperative hypotension is associated with shortened overall survival after lung cancer surgery
Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer
Association between intermediate end points, progression-free survival, and overall survival in first-line advanced or recurrent endometrial cancer
Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
Progression-free or overall survival…revisited in BOLERO-2
Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database
Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma
Venetoclax ex vivo functional profiling predicts improved progression-free survival
Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
A novel DNA methylation signature to improve survival prediction of progression-free survival for testicular germ cell tumors
Intraoperative hypotension is associated with shortened overall survival after lung cancer surgery